194 related articles for article (PubMed ID: 34476808)
21. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
Theunissen PMJ; Sedek L; De Haas V; Szczepanski T; Van Der Sluijs A; Mejstrikova E; Nováková M; Kalina T; Lecrevisse Q; Orfao A; Lankester AC; van Dongen JJM; Van Der Velden VHJ;
Br J Haematol; 2017 Jul; 178(2):257-266. PubMed ID: 28419441
[TBL] [Abstract][Full Text] [Related]
22. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
[TBL] [Abstract][Full Text] [Related]
23. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
[TBL] [Abstract][Full Text] [Related]
24. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
[TBL] [Abstract][Full Text] [Related]
27. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
[TBL] [Abstract][Full Text] [Related]
28. United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
Chatterjee G; Patkar N
Br J Haematol; 2023 Feb; 200(3):277-279. PubMed ID: 36282207
[TBL] [Abstract][Full Text] [Related]
29. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
Soh KT; Wallace PK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
[TBL] [Abstract][Full Text] [Related]
31. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
33. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
Momen N; Tario J; Fu K; Qian YW
J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
[TBL] [Abstract][Full Text] [Related]
34. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
[TBL] [Abstract][Full Text] [Related]
36. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
Das N; Gupta R; Gupta SK; Bakhshi S; Seth R; Kumar C; Rai S; Singh S; Prajapati VK; Gogia A; Sahoo RK; Sharma A; Kumar L
Ann Hematol; 2021 Oct; 100(10):2487-2500. PubMed ID: 34236495
[TBL] [Abstract][Full Text] [Related]
37. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Ribera J; Granada I; Morgades M; González T; Ciudad J; Such E; Calasanz MJ; Mercadal S; Coll R; González-Campos J; Tormo M; García-Cadenas I; Gil C; Cervera M; Barba P; Costa D; Ayala R; Bermúdez A; Orfao A; Ribera JM;
Br J Haematol; 2022 Feb; 196(3):670-675. PubMed ID: 34549416
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy.
Chen X; Gao Q; Roshal M; Cherian S
Cytometry B Clin Cytom; 2023 May; 104(3):205-223. PubMed ID: 36683279
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
[TBL] [Abstract][Full Text] [Related]
40. Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
Ikoma-Colturato MRV; Bertolucci CM; Conti-Spilari JE; Oliveira E; Simioni AJ; Figueredo-Pontes LL; Furtado FM; Alegretti AP; Azambuja AP; Gevert F; Gomes BE; Avelar DMV; Soares ACCV; Ramos PM; Santos B; Cortez ML; Beltrame MP; Bacal NS; Wagner A; Lucena-Silva N; Sandes AF; Cunha F; Oliveira GHM; Costa ES; Yamamoto M
Br J Haematol; 2023 Feb; 200(3):381-384. PubMed ID: 36222259
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
